NYSEAMERICAN:MYOMyomo Stock Price, Forecast & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Myomo.

Myomo is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Myomo.

Myomo Inc (NYSEAMERICAN:MYO) released its quarterly earnings results on Thursday, May, 14th. The company reported ($2.51) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($2.06) by $0.45. The company earned $1.01 million during the quarter, compared to the consensus estimate of $0.78 million. View Myomo's earnings history.

Myomo updated its second quarter 2020 Pre-Market earnings guidance on Monday, June, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $600K - 700K, compared to the consensus revenue estimate of $370K.

3 Wall Street analysts have issued twelve-month price objectives for Myomo's stock. Their forecasts range from $2.00 to $15.00. On average, they expect Myomo's share price to reach $8.50 in the next year. This suggests a possible upside of 115.7% from the stock's current price. View analysts' price targets for Myomo.

Media headlines about MYO stock have trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Myomo earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Myomo.

Myomo saw a decrease in short interest in June. As of June 30th, there was short interest totaling 73,600 shares, a decrease of 22.3% from the June 15th total of 94,700 shares. Based on an average daily trading volume, of 343,400 shares, the short-interest ratio is currently 0.2 days. Currently, 2.7% of the shares of the stock are sold short. View Myomo's Current Options Chain.

Some companies that are related to Myomo include Protech Home Medical (PHM), Polarean Imaging (POLX), Respiri (RSH), Anteo Diagnostics (ADO), Universal Biosensors (UBI), Oventus Medical (OVN), LBT Innovations (LBT), Impedimed (IPD), Inspiration Healthcare Group (IHC), Helius Medical Technologies (HSM), Azure Healthcare (AZV), Surgical Innovations Group (SUN), Heramed (HMD), Analytica (ALT) and Xtant Medical (XTNT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myomo investors own include Genocea Biosciences (GNCA), Remark (MARK), Protalix Biotherapeutics (PLX), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Ring Energy (REI), Ring Energy (REI) and Roku (ROKU).

Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."

Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MYO stock can currently be purchased for approximately $3.94.

Myomo has a market capitalization of $11.09 million. Myomo employs 45 workers across the globe.

The official website for Myomo is myomo.com.

Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company can be reached via phone at +1-617-9969058.